Table 2.

Subgroup analysis results for Laser Doppler Imaging (LDI) blood flow at 1-month follow-up.

		Absolute LDI Blood Flow at 1-month			Change in LDI Blood Flow at 1-month
Group	n	Between-arm difference	95%CI	p-value*	Between-arm difference	95%CI	Interaction p-value**
All	40	-27.49	-50.20 to -4.79	0.018	-30.08	-56.19 to -3.98	0.024
Limited	25	-16.78	-48.07 to 14.51	0.293	-20.31	-50.78 to 10.16	0.191
Diffuse	15	-45.34	-75.24 to -15.44	0.003	-46.37	-94.25 to 1.52	0.058
Short duration of RP	20	-3.52	-28.15 to 21.17	0.780	-37.16	-74.74 to 0.42	0.053
Long duration of RP	20	-51.46	-87.21 to -15.71	0.005	-23.01	-59.96 to 13.95	0.222
On CCBs at baseline	29	-22.73	-51.82 to 6.36	0.126	-37.52	-71.61 to -3.42	0.031
Not on CCBs at baseline	11	-40.03	-71.40 to -8.66	0.012	-10.47	-40.15 to 19.20	0.489
Medsger Severity 1	11	-28.44	-64.73 to -7.84	0.124	-42.63	-95.53 to 10.26	0.114
Medsger Severity 2	15	-33.81	-67.90 to 0.29	0.052	-30.41	-67.43 to 6.62	0.107
Medsger Severity 3	13	-15.29	-65.60 to -35.02	0.551	-10.77	-61.21 to 39.7	0.676

Btx-A: Botulinum toxin A. CI: Confidence Interval. RP: Raynaud's Phenomenon. CCB: Calcium Channel Blocker.

^*P-values from the model compared absolute outcomes at 1-month follow-up visit between treatment arms (Btx-A - placebo).

^**Interaction p-values from the model compared changes in outcomes from baseline to 1-month follow-up visit between treatment arms (Btx-A - placebo).